Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

priority access

- PMLiVE

India’s patents versus India’s patients

What the Roche Pegasys case means for big pharma

- PMLiVE

AstraZeneca removes R&D and commercial heads

Pascal Soriot's leadership shake-up will see Martin Mackay and Tony Zook leave

- PMLiVE

Scotland launches £21m fund for rare conditions

Will pay for orphan medicines not recommended by the SMC

- PMLiVE

Merck suspends Tredaptive worldwide

Trial demonstrates increased risk of serious adverse events

Novartis building

Novartis parts with Eisai to go it alone with COPD drugs

Ends co-promotion agreement for Onbrez, Seebri and QVA149

- PMLiVE

NICE set to approve Novartis eye drug Lucentis

Final draft guidance says treatment is cost-effective in diabetic macular oedema

- PMLiVE

Actavis mounts patent challenge on Velcade in US

Plans to launch own version of Takeda’s cancer drug

Novartis building

Novartis’ Exjade gets EU approval for thalassaemia

First oral treatment for condition characterised by red blood cell problems and anaemia

- PMLiVE

Merck drops plans to file Tredaptive in US

Pharma company also says cardiovascular drug should not be prescribed to new patients in Europe

- PMLiVE

Pharma ‘influencing Polish drug market’

Leads to recommendations for expensive and ineffective medicines says study

- PMLiVE

Merck’s oncology vaccine fails lung cancer trial

Stimuvax unable to demonstrated improvement in overall survival

- PMLiVE

Year-end FDA approvals for Novartis, GSK drugs

Agency gives go-ahead to Cushing’s disease treatment Signifor and raxibacumab for inhalational anthrax

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links